Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Integumen Debt Conversion

1 May 2019 11:00

RNS Number : 7356X
Venn Life Sciences Holdings PLC
01 May 2019
 

1 May 2019

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Integumen plc ("Integumen") Debt Conversion - Related Party Transaction

Venn Life Sciences, an Integrated Drug Development Partner offering a combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations, announces, that following the approval of Integumen shareholders and under the terms of the Venn Debt Conversion Agreement the debt of £421,000 owed by Integumen, has been converted into 30,071,428 new Integumen ordinary shares at a price of 1.4 pence, conditional upon admission.

Separate to this conversion, Venn has sold 42,244,682 ordinary shares for a total consideration of €575,000. Following Admission of the conversion shares referred to above, Venn will hold 30,071,428 ordinary shares.

Venn has agreed that any disposal of Integumen ordinary shares held by them for the two years following Admission will be effected through Integumens broker so as to ensure an orderly market in the ordinary shares.

The debt conversion is a related party transaction for the purposes of Rule 13 of the AIM Rules for companies. As Tony Richardson is Integumens Chairman, the Chief Executive of Venn, and therefore is not considered to be independent for the purposes of considering and negotiating the Venn Debt Conversion Agreement. The Directors (other than Tony Richardson) consider, having consulted with Arden Partners plc, the Company's nominated adviser, that the terms of the Venn Debt Conversion Agreement and conversion by Venn are fair and reasonable in so far as its Shareholders are concerned.

 

Enquiries:

Venn Life Sciences Holdings plc Tel: +353 1 5499 341Tony Richardson, Chief Executive Officer

Arden Partners plc Tel: +44 (0)2076145900

John Llewellyn-Lloyd, Ruari McGirr, Benjamin Cryer

Davy (ESM Adviser and Joint Broker) Tel: +353 (0)1 679 6363Fergal Meegan / Matthew de Vere White (Corporate Finance)

 

 

DEFINITIONS

The following words and expressions shall have the following meanings in this document unless the context otherwise requires:

 

"Venn Debt Conversion Agreement"

the agreement dated 11 April 2019 between (1) the Company and (2) Venn to convert the Venn Debt into the Venn Debt Shares

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCSSASUFFUSEEI
Date   Source Headline
30th Jan 201511:57 amRNSHolding(s) in Company
28th Jan 201512:05 pmRNSGrant of Options
6th Jan 20157:00 amRNSDirectorate Change
23rd Dec 20147:00 amRNSYear End Update
10th Dec 20147:00 amRNSInnovenn Board Appointment
20th Nov 20147:00 amRNSInnovenn commences production at new facilities
11th Nov 20147:00 amRNSEUR1.4m contract win with US firm
21st Oct 20147:00 amRNSEUR1.2m Contract with Global Pharmaceutical Comp
30th Sep 20147:01 amRNSStrategic Investment in InnoVenn
30th Sep 20147:00 amRNSInterim Results
18th Sep 201411:29 amRNSHolding(s) in Company
8th Sep 20143:00 pmRNSIssue of Consideration Shares
8th Sep 20147:00 amRNSEUR2.4m contract for pan-European coronary study
5th Aug 20147:00 amRNSAcquisition of French CRO
24th Jun 20143:44 pmRNSResult of AGM
24th Jun 20147:00 amRNSAGM Statement
19th Jun 20147:00 amRNSSkin science patent grant
27th May 20142:26 pmRNSDirector's Dealing
16th May 201412:25 pmRNSMajor contract win
16th May 201412:23 pmRNSFinal Results
2nd Apr 201412:21 pmRNSHolding(s) in Company
31st Mar 201411:48 amRNSResult of general meeting
18th Mar 20142:46 pmRNSUpdate on the Acquisition of Evocutis plc
14th Mar 20147:00 amRNSPlacing to raise £1 million & Notice of GM
13th Mar 20141:00 pmRNSUpdate of Evocutis plc acquisition
13th Mar 20141:00 pmRNSResult of AGM and General Meeting
26th Feb 20147:00 amRNSAcquisition of the trading assets of Evocutis PLC
26th Feb 20147:00 amRNSCirc re. Disposal and Notice of GM
13th Jan 20147:00 amRNSUpdate re: Aquisition of German based CRO
9th Dec 20137:00 amRNSAcquisition of Belfast Based CRO
29th Nov 201312:16 pmRNSHolding(s) in Company
31st Oct 20137:00 amRNSAcquisition
11th Oct 20131:31 pmRNSHolding(s) in Company
3rd Oct 201312:55 pmRNSDirector's Dealing
2nd Oct 20132:17 pmRNSChange of Registered Office
27th Sep 20137:00 amRNSInterim Results
23rd Jul 20133:39 pmRNSResult of AGM
13th Jun 20137:00 amRNSFinal Results
17th May 20137:00 amRNSInnovation division launch & co-development
7th May 20138:36 amRNSHolding(s) in Company
26th Apr 20137:09 amRNSProject wins
9th Apr 20137:00 amRNSSenior Management Appointments
14th Mar 20137:00 amRNSBoard Appointment
5th Mar 20131:19 pmRNSHolding(s) in Company
28th Feb 201312:47 pmRNSDirector/PDMR Shareholding
21st Feb 20139:49 amRNSDirector/PDMR Shareholding
7th Feb 20137:00 amRNSVenn Life Sciences expands into Russia
14th Dec 20127:00 amRNSAdmission to trading on AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.